Chronic Lower Back Pain "As we enter the second half of 2024, it is an opportune time to reflect on our recent achievements," said Timothy Warbington, Chief Executive Officer. "Many of our successes thus far in 2024 were the result of investments we have made in prior years combined with our steadfast adherence to operating a lean corporate structure, and engaging with our global partners and institutions to support the rapid translation of novel therapies into patients. Manufactured over six billion AlloSt ...

The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company's iPSCelz® program, which is validated by Greenstone Biosciences Inc. ("Greenstone"). The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated mesenchymal cells and T-regulatory cells. iPSCelz®, which is protected by trade secrets and published U.S. patents, utilizes the companies xeno-free human perinatal cell li ...

Core Insights - Creative Medical Technology Holdings, Inc. has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin, marking a significant milestone in their regenerative medicine efforts [1][3] - The iPSC clinical line used for this development is part of the iPSCelz® program, which is validated by Greenstone Biosciences Inc. and is currently utilized in several FDA cleared clinical programs [2][4] - The company aims to leverage this advancement for both clinical applications of human Islet Cells and the production of stand-alone human insulin, with ongoing strategic discussions for future collaborations [3] Company Overview - Creative Medical Technology Holdings, Inc. specializes in stem cell technology across various fields including immunotherapy, urology, neurology, and orthopedics [5] - The iPSCelz® program utilizes a xeno-free human perinatal cell line derived from qualified human donors, which is then converted into iPS cells through a proprietary reprogramming process [4] Leadership Commentary - Timothy Warbington, President and CEO, emphasized the importance of this development as a reflection of the company's leadership in therapy development and its potential to save significant research and development time and costs [3] - The company is committed to achieving milestones in a cost-efficient manner while adhering to regulatory requirements, indicating a prudent allocation of resources [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-53500 | --- | --- | --- | |--------------------------------------------------|--------------------------|-----------------------------------------------------| | Nevada | | 87-0622284 | | (State or other jurisdiction of | | (I.R.S. ...

In August 2017, we completed recruitment on a clinical trial of the CaverStem® procedure conducted by the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Following completion of recruitment and treatment of the study subjects, an independent Institutional Review Board (IRB) overseeing the study validated the procedure as safe. In the same time frame, other worldwide, peer-reviewed and published clinical trials using the same procedure validated the efficacy of the ED treatment. As a ...

Creative Medical Technology Holdings, Inc. (CELZ) announced that the FDA has granted an Orphan Drug designation to its cell-based immunotherapy, CELZ-101, also known as ImmCelz.CELZ-101 is being developed for the prevention of allograft rejection in patients undergoing pancreatic islet cell transplantation for the treatment of type 1 diabetes.Type 1 diabetes is marked by extreme fluctuations in blood glucose levels.The perquisites that come from Orphan Drug designation include assistance in the drug develop ...

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals. This groundbreaking therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in med ...

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell trans ...

Following the approval of the Company's Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company's outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company's Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse s ...

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ...